- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.02. | OKYO Pharma LTD: OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress | 234 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 23.02. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 20.02. | Piper Sandler startet Coverage für OKYO Pharma mit 'Overweight'-Rating | 2 | Investing.com Deutsch | ||
| 20.02. | Piper Sandler initiates OKYO Pharma stock with Overweight rating | 1 | Investing.com | ||
| 13.02. | OKYO Pharma kündigt Aktienplatzierung im Wert von 20 Millionen US-Dollar an | 1 | Investing.com Deutsch | ||
| 13.02. | OKYO Pharma prices public offering at $1.85/share to raise up to $20M | 3 | Seeking Alpha | ||
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| 13.02. | OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares | 416 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 12.02. | OKYO Pharma launches underwritten public offering of ordinary shares | 1 | Seeking Alpha | ||
| 12.02. | OKYO Pharma Announces Public Offering of Ordinary Shares | 335 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 11.02. | OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners | 552 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 10.02. | OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer | 283 | GlobeNewswire (Europe) | Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate, a blockbuster orphan therapy in corneal diseaseDr. Mantelli... ► Artikel lesen | |
| 10.02. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 30.01. | OKYO Pharma präsentiert Studienergebnisse zu Urcosimod auf jährlicher ASCRS-Tagung | 1 | Investing.com Deutsch | ||
| 30.01. | OKYO Pharma to present urcosimod NCP study results at ASCRS meeting | 1 | Investing.com | ||
| 30.01. | OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting | 333 | GlobeNewswire (Europe) | LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 30.01. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 29.01. | H.C. Wainwright reiterates Buy rating on OKYO Pharma stock with $7 price target | 1 | Investing.com | ||
| 28.01. | OKYO Pharma meldet erfolgreiches FDA-Treffen zur klinischen Studie mit Urcosimod | - | Investing.com Deutsch | ||
| 28.01. | OKYO Pharma erhält grünes Licht der FDA für entscheidende NCP-Studie | - | Investing.com Deutsch | ||
| 28.01. | OKYO Pharma receives FDA alignment on Phase 2b/3 trial for NCP treatment | 2 | Investing.com |
1 2 3 4 Weiter >>
69 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IDEXX LABORATORIES | 525,40 | -0,08 % | ROUNDUP: IDEXX Laboratories Guides FY26 In Line With Estimates | WASHINGTON (dpa-AFX) - While reporting financial results for the fourth quarter on Monday, pet healthcare provider IDEXX Laboratories, Inc. (IDXX) initiated its earnings and revenue guidance... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,444 | -1,50 % | Why Are BioXcel Therapeutics Shares Down Friday? | ||
| VOYAGER THERAPEUTICS | 3,506 | -0,17 % | Voyager Therapeutics, Inc.: Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,001 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 4,224 | +5,60 % | ANAVEX LIFE SCIENCES CORP im Ruhemodus vor dem nächsten Impuls | ||
| CELLAVISION | 14,460 | +0,98 % | CellaVision: Solid Quarter driven by Strong Performance in Americas | Organic sales growth:Q4, 2025: 12.2% (-7.4)EBITDA margin:Q4, 2025: 33% (33)Oktober 1st - December 31st, 2025Net sales increased by 5.6% (-7.0) to SEK 197 m (187).Sales increased organically by 12.2%... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 4,120 | +0,98 % | Precision BioSciences stellt präklinische Daten zur DMD-Therapie vor | ||
| ZYMEWORKS | 23,000 | +10,58 % | Stifel raises Zymeworks stock price target on royalty deal value | ||
| VTV THERAPEUTICS | 30,600 | +4,08 % | vTv Therapeutics Inc.: vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health | HIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in collaboration... ► Artikel lesen | |
| QUOIN PHARMACEUTICALS | 6,900 | -1,43 % | Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome | Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status Quoin Initiating the Establishment of a Japanese Subsidiary to Facilitate... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 4,630 | 0,00 % | Neuphoria Therapeutics, Inc.: Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions | BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies... ► Artikel lesen | |
| PLIANT THERAPEUTICS | 1,140 | +0,88 % | Pliant Therapeutics, Inc.: Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors | One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment... ► Artikel lesen | |
| MIRA PHARMACEUTICALS | 1,000 | -0,99 % | MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2 | Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings MIAMI, FLORIDA / ACCESS... ► Artikel lesen | |
| NUVATION BIO | 4,735 | 0,00 % | Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch | ||
| ONCONETIX | 0,520 | +1,96 % | Onconetix, Inc.: Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement | CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology... ► Artikel lesen |
OKYO PHARMA LIMITED gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,710 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.